TRANSFORMATIONAL MEDICINES THAT MAKE A DIFFERENCE
DEAD

Serial Number

97931495

Owner

THERAVANCE BIOPHARMA R&D IP, LLC

Attorney

Beth H. Alter

Filing Date

May 11, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TRANSFORMATIONAL MEDICINES THAT MAKE A DIFFERENCE Trademark

Serial Number: 97931495

TRANSFORMATIONAL MEDICINES THAT MAKE A DIFFERENCE is a trademark filed by THERAVANCE BIOPHARMA R&D IP, LLC on May 11, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

THERAVANCE BIOPHARMA R&D IP, LLC (14 trademarks)

901 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

Entity Type: 16

Trademark Details

Filing Date

May 11, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceuticals, namely, medical and veterinary pharmaceutical preparations for the treatment of human and animal diseases of the autonomic, respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; sanitary preparations for medical purposes; dietetic food adapted for medical or veterinary use; diagnostic preparations and materials, namely, diagnostic agents, preparations and substances for medical, pharmaceutical and veterinary purposes; disinfectants and antiseptics; medical dressings, coverings and applicators, namely, bandages for dressings, gauze for dressings, dressings for wounds, burns and surgery, cotton and synthetic swabs for medical use, adhesive plasters for medical use, inhalers filled with pharmaceutical products for the treatment of autonomic, respiratory diseases and disorders; natural remedies, namely, natural remedy preparations for the treatment of gastro-intestinal conditions, hormonal and chemical imbalances and sleep disorders, and for the treatment of human diseases and disorders of the autonomic, respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; natural dietary supplements for the treatment of human diseases and disorders of the autonomic, respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; pharmaceutical products for treatment of human diseases of the respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; pharmaceutical preparations for the treatment of cancer and pain; pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of ocular and dermatological diseases and disorders; pharmaceutical preparations and substances for the treatment of bacterial and viral infections, namely, anti-infectives

Scientific and technological services, namely, scientific research, analysis, design and testing, in the field of pharmaceuticals and medicine; medical and pharmacological research services in the field of pharmaceuticals and medicine; natural science services, namely, scientific research, analysis, design and testing in the field of natural medicine and natural remedies; testing, namely, testing of pharmaceuticals and providing medical testing services in the field of research into human diseases of the autonomic, respiratory, endocrine, circulatory, gastrointestinal, genito-urinary, integumentary, immune and central nervous system; authentication, namely, authentication of pharmaceutical and medicines; quality control for others; scientific investigation for medical purposes; bacteriological, chemical and biological investigation being scientific investigation for medical purposes

Filing History

ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
May 15, 2024 MAB1
ABANDONMENT - EXPRESS MAILED
May 15, 2024 ABN1
ASSIGNED TO EXAMINER
May 14, 2024 DOCK
ASSIGNED TO EXAMINER
May 14, 2024 DOCK
TEAS EXPRESS ABANDONMENT RECEIVED
May 6, 2024 EXAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 6, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 10, 2023 NWOS
NEW APPLICATION ENTERED
May 15, 2023 NWAP